Viela Bio's Days Sales Outstanding for the
three
months ended in Dec. 2020 was 38.57.
Viela Bio's Days Inventory for the
three
months ended in Dec. 2020 was 28.75.
Viela Bio's Days Payable for the
three
months ended in Dec. 2020 was 349.67.
Therefore, Viela Bio's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2020 was -282.35.
Viela Bio Cash Conversion Cycle Historical Data
The historical data trend for Viela Bio's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viela Bio's Cash Conversion Cycle
For the Biotechnology subindustry, Viela Bio's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viela Bio's Cash Conversion Cycle Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viela Bio's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Viela Bio's Cash Conversion Cycle falls into.
Viela Bio Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Viela Bio's Cash Conversion Cycle for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio (NAS:VIE) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Viela Bio Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Viela Bio's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIE has been successfully added to your 